Inclusion Criteria:  Histologically or cytologically confirmed pancreatic cancer; Unresectable locally advanced or metastatic disease ; Documented disease progression after first-line treatment gemcitabine based therapy ECOG: 0-1; Adequate organ and bone marrow function; sign an informed consent.  Exclusion Criteria:  Active CNS metastasis; Uncontrolled tumor-related pain; Clinically significant GI disorders; Significant cardiovascular disease; Active infection or uncontrolled fever; Pregnant or breast feeding patients; Allergic to a drug ingredient or component; The investigators determined that other conditions were inappropriate for participation in this clinical trial.